Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

doi:10.1016/j.ejca.2017.04.007

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Back to search

Article

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.

European journal of cancer (Oxford, England : 1990) - 1 Jul 2017

Blank Christian U, Larkin James, Arance Ana M, Hauschild Axel, Queirolo Paola, Del Vecchio Michele, Ascierto Paolo A, Krajsova Ivana, Schachter Jacob, Neyns Bart, Garbe Claus, Chiarion Sileni Vanna, Mandalà Mario, Gogas Helen, Espinosa Enrique, Hospers Geke A P, Miller Wilson H, Robson Susan, Makrutzki Martina, Antic Vladan, Brown Michael P

Abstract excerpt

BACKGROUND: The orally available BRAF kinase inhibitor vemurafenib is an effective and tolerable treatment option for patients with metastatic melanoma harbouring BRAFV600 mutations. We assessed the safety of vemurafenib in a large population of patients with few alternative treatment options; we report updated 2-year safety. METHODS: This was an open-label, multicentre study of vemurafenib (960 mg bid) in...

Topics

Adult
Aged
Antineoplastic Agents
Brain Neoplasms
Disease Progression
Disease-Free Survival
Female
Follow-Up Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Humans

Indoles

Male

Melanoma

Middle Aged

Mutation

Proto-Oncogene Proteins B-raf

Skin Neoplasms

Sulfonamides

Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 28501764
DOI: 10.1016/j.ejca.2017.04.007

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.PMID 28501764Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Semantic proximity Read ↗

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Semantic proximity Read ↗

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity Read ↗

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.Semantic proximity Read ↗

Long-term vemurafenib therapy in advanced melanoma patients: cutaneous toxicity and prognostic implications.Semantic proximity Read ↗

Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.